Free Trial
NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

Penumbra logo
$270.40 -2.33 (-0.85%)
Closing price 03:59 PM Eastern
Extended Trading
$270.94 +0.53 (+0.20%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Penumbra Stock (NYSE:PEN)

Key Stats

Today's Range
$269.51
$275.18
50-Day Range
$236.12
$276.01
52-Week Range
$148.00
$277.89
Volume
317,563 shs
Average Volume
502,382 shs
Market Capitalization
$10.38 billion
P/E Ratio
314.42
Dividend Yield
N/A
Price Target
$261.36
Consensus Rating
Moderate Buy

Company Overview

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

PEN MarketRank™: 

Penumbra scored higher than 77% of companies evaluated by MarketBeat, and ranked 238th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Penumbra has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Penumbra's stock forecast and price target.
  • Earnings Growth

    Earnings for Penumbra are expected to grow by 37.37% in the coming year, from $2.81 to $3.86 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Penumbra is 314.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 111.13.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Penumbra is 314.42, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 88.94.

  • Price to Earnings Growth Ratio

    Penumbra has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Penumbra has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Penumbra's valuation and earnings.
  • Percentage of Shares Shorted

    4.79% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 3.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Penumbra does not currently pay a dividend.

  • Dividend Growth

    Penumbra does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.79% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 3.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Penumbra has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Penumbra this week, compared to 9 articles on an average week.
  • Search Interest

    Only 1 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,129,483.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Penumbra is held by insiders.

  • Percentage Held by Institutions

    88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Penumbra's insider trading history.
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Penumbra (NYSE:PEN) Coverage Initiated at UBS Group
Penumbra initiated with a Buy at UBS
See More Headlines

PEN Stock Analysis - Frequently Asked Questions

Penumbra's stock was trading at $237.48 at the start of the year. Since then, PEN stock has increased by 13.9% and is now trading at $270.4010.
View the best growth stocks for 2025 here
.

Penumbra, Inc. (NYSE:PEN) issued its earnings results on Wednesday, October, 30th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.16. The business's revenue was up 11.1% compared to the same quarter last year.

Penumbra's board initiated a stock buyback plan on Tuesday, August 13th 2024, which permits the company to repurchase $200,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its shares are undervalued.

Penumbra's top institutional shareholders include WCM Investment Management LLC (0.15%), Hantz Financial Services Inc. (0.13%), Retirement Systems of Alabama (0.12%) and Wilmington Savings Fund Society FSB (0.08%). Insiders that own company stock include Adam Elsesser, Arani Bose, Johanna Roberts, Lambert Shiu, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing and Thomas Wilder.
View institutional ownership trends
.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/30/2024
Today
1/28/2025
Next Earnings (Estimated)
2/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
4,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$261.36
High Stock Price Target
$323.00
Low Stock Price Target
$210.00
Potential Upside/Downside
-4.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

Net Income
$90.95 million
Pretax Margin
1.26%

Debt

Sales & Book Value

Annual Sales
$1.06 billion
Cash Flow
$2.79 per share
Book Value
$30.55 per share

Miscellaneous

Free Float
36,460,000
Market Cap
$10.46 billion
Optionable
Optionable
Beta
0.52

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:PEN) was last updated on 1/28/2025 by MarketBeat.com Staff
From Our Partners